Investors / filer profile

Perceptive Advisors LLC

active in 5 companies · 1 of 1 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 17
Filings: 5
Companies: 2026-08-26
Last filed

EDGAR · CIK 0001224962 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+65.6%

median move per position

+10.9%

S&P 500 median, same spans

1 of 1

beat the S&P ~6mo later

1 position still inside the ~6-month window — not scored yet.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$9.42M bought · −$526.7K sold

All filings on record

Every Form 4 transaction we track for this filer


IMTXImmatics N.V.	Buy $7.50M · 863,060 sh	2026-08-26	—
MGTXMeiraGTx Holdings plc	Return $18.19M · 2,300,000 sh	2025-12-31	—
LONALeonaBio, Inc.	Grant $2.09M · 329,756 sh	2025-12-23	—
LONALeonaBio, Inc.	Grant $6.28M · 989,270 sh	2025-12-23	—
LYRALyra Therapeutics, Inc.	Sell $12.5K · 3,213 sh	2025-11-13	—
LYRALyra Therapeutics, Inc.	Sell $111.5K · 28,597 sh	2025-11-13	—
LYRALyra Therapeutics, Inc.	Sell $3.6K · 883 sh	2025-11-12	—
LYRALyra Therapeutics, Inc.	Sell $31.9K · 7,862 sh	2025-11-12	—
LYRALyra Therapeutics, Inc.	Sell $2.3K · 537 sh	2025-11-11	—
LYRALyra Therapeutics, Inc.	Sell $20.6K · 4,783 sh	2025-11-11	—

IMTXBuy

2026-08-26 · Immatics N.V.

$7.50M

—

MGTXReturn

2025-12-31 · MeiraGTx Holdings plc

$18.19M

—

LONAGrant

2025-12-23 · LeonaBio, Inc.

$2.09M

—

LONAGrant

2025-12-23 · LeonaBio, Inc.

$6.28M

—

LYRASell

2025-11-13 · Lyra Therapeutics, Inc.

$12.5K

—

LYRASell

2025-11-13 · Lyra Therapeutics, Inc.

$111.5K

—

LYRASell

2025-11-12 · Lyra Therapeutics, Inc.

$3.6K

—

LYRASell

2025-11-12 · Lyra Therapeutics, Inc.

$31.9K

—

LYRASell

2025-11-11 · Lyra Therapeutics, Inc.

$2.3K

—

LYRASell

2025-11-11 · Lyra Therapeutics, Inc.

$20.6K

—

Newest 10 of 17 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.